Mohandas Narla, head of the laboratory of red cell physiology at New York Blood Center Enterprises, began his term as president of the American Society of Hematology. He will serve a year-long term through December 2024.
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
